Insmed Patent-Cliff Exposure & CMS Drug Spending Portfolio

Insmed (US): 2 reconciled FDA prescription therapies, $0 2024 CMS Part D & Medicaid spend, and $7,333 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies2
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2035-01-01
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
California HCAI SB 17 FilingsSpecialty launch notice ($7,333 intro WAC)